NOVOXEL LTD

Novoxel and GPOphtho Partner to Expand Access to FDA-Cleared Tixel Device for Dry Eye Treatment Across US

- Novoxel Inc. and GPOphtho have finalized a strategic agreement to expand access to the Tixel device family for treating dry eye and aesthetic procedures nationwide. - The Tixel i device specifically targets Meibomian Gland Dysfunction (MGD) with a 2-minute treatment for both eyes, supported by recent clinical trial data showing safety and efficacy. - The FDA-cleared device uses proprietary Thermo-Mechanical Action technology to provide non-invasive treatments without needles, bleeding, or radiation exposure. - The partnership enables eyecare physicians to integrate both functional dry eye treatments and cosmetic procedures, creating new revenue streams through discounted pricing packages.